Skip to content
Pulse Today delivers current health news, medical breakthro…

The Zimbabwean Government Turns Down ‘Lopsided’ American Healthcare Assistance Deal Over Data Fears

Medical funding image
The proposed US funding was aimed at programmes for treating and preventing HIV/Aids, TB, and malarial diseases.

The nation of Zimbabwe has turned down a significant American health deal worth $367m (272 million pounds) over five years over Washington's insistence on sensitive data.

This rejection became public after a government memo dated December was disclosed, revealing that Head of State Emmerson Mnangagwa believed the deal was "skewed".

A government representative has since stated that the US was demanding access to genetic material for research and commercial purposes but refused to guarantee the benefits from future vaccines.

"We will now turn to the difficult and regrettable process of ending our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.

Her embassy indicated the US had furnished over $1.9bn in health funding to Zimbabwe during the past twenty years.

A doctors' association in Zimbabwe has appealed for further negotiations to secure a deal acceptable to all parties so the country's critical HIV treatment initiative can be sustained.

Broader Background

This development comes after a similar case in Kenya, where a high court suspended a related deal with the US after legal challenges were raised about the safety of citizens' health data.

After returning to the presidency recently, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).

USAID had overseen assistance for the American government, but Trump claimed its spending was "inefficient" and his administration was seeking direct bilateral agreements to boost transparency and accountability.

According to reports, Sixteen nations in Africa have so far signed similar health pacts, constituting over $18.3bn in new funding.

Details of the Declined Deal

The funds for Zimbabwe was intended to gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".

"We are confident this cooperation would have delivered significant advantages for the people of Zimbabwe, especially the 1.2 million currently on HIV treatment via American-funded programmes," Tremont said.

However, official spokesman Nick Mangwana maintained the arrangement was "asymmetrical".

"The proposal required Zimbabwe to provide its biological resources and data for a long time, with no equivalent assurance of benefiting from any medical innovations – such as new medicines or tests – that might be developed from that provided information," Mangwana explained.

"Effectively, our country would supply the raw materials for medical research without any certainty that the resulting innovations would be accessible to our citizens if a new health crisis arise."

National Interest and International Frameworks

Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one deals were undermining systems previously set up via the international health agency.

The spokesperson gave as an example its Pandemic Benefit-Sharing system designed to deal with future pandemics.

"This mechanism is intended to ensure that when a nation contributes its samples, the resulting advantages – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the resources to create them."

The government's concerns over the US deal "are not meant as hostility towards the US," Mangwana stressed.

"We welcome further discussions with our American counterparts on how future co-operation might be structured in a manner that honours the sovereignty and interests of each country."

Health Experts Reaction

Medical experts expressed it acknowledged the government's concerns, but recommended that talks need to persist since a large portion of the country's Aids initiatives were funded by external financing.

"If specific concerns arise, such as those relating to data governance or agreement terms, these can often be addressed via detailed discussion and negotiated safeguards," it added.

The halted deal emphasises the ongoing tensions between accepting crucial international aid and protecting national sovereignty in an increasingly data-driven world.

Written by

Natalie Miranda

Dr. Vance is a medical journalist with over a decade of experience covering public health and clinical research.

Pulse Today

Type to search articles.